Synthesis of Tri-substituted Imidazo-Thiadiazole Derivatives - Mogal, Azmin M.; Noolvi, M. N.
36,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Broschiertes Buch

In this study we have synthesized and evaluated some newt tri-substitute imidazo [2, 1-b]- 1,3,4- thiadiazole derivatives comprising coumarin and imidazo [2, 1-b]- 1,3,4- thiadiazole moieties. We have reported a series of imidazo [2, 1-b]- 1,3,4- thiadiazole analogues to target MAPK. The compounds were synthesized by conventional methods and reaction process was monitored by TLC using suitable mobile phase and melting points of synthesized compounds were also determined. Furthermore, synthesized compounds were also characterized and confirmed by IR, 1H-NMR, 13C-NMR and Mass spectra. Two…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
In this study we have synthesized and evaluated some newt tri-substitute imidazo [2, 1-b]- 1,3,4- thiadiazole derivatives comprising coumarin and imidazo [2, 1-b]- 1,3,4- thiadiazole moieties. We have reported a series of imidazo [2, 1-b]- 1,3,4- thiadiazole analogues to target MAPK. The compounds were synthesized by conventional methods and reaction process was monitored by TLC using suitable mobile phase and melting points of synthesized compounds were also determined. Furthermore, synthesized compounds were also characterized and confirmed by IR, 1H-NMR, 13C-NMR and Mass spectra. Two selected compounds were sent to NCI for anticancer screening and got results of both the compounds (6a & 6b). Compound 6a inhibited various cell lines with growth percentage of 140.30. Compound 6b inhibited different cell lines with growth percentage of 54.60. So, we conclude that, imidazo [2, 1-b]- 1,3,4- thiadiazole derivative containing Thiocynaide group (6a) is showing good anticancer activity than amino group-containing imidazo [2, 1-b]- 1,3,4- thiadiazole compound (6b). These results could offer an excellent framework in this field that may lead to discovery of potent anticancer agents.
Autorenporträt
La signorina Bhatt Darshana K. lavora come Executive in LIMS 3.4.0.E Reviewer presso JB Chemicals & Pharmaceutical Limited (JBCPL), Panoli, Ankleshwar. Ha conseguito un master in chimica farmaceutica presso la Gujarat Technological University di Ahmadabad e ha un'esperienza di un anno nella chimica sintetica e nella ricerca sul cancro.